[
Abstract]
[
Full Text HTML]
[
Full Text PDF] （in Japanese / 1420KB）
[PDF: Members Only] J.Jpn. Surg. Soc.. 124(3): 276-282, 2023
Feature topic
CURRENT STATUS AND FUTURE PROSPECTS OF STRATIFIED MEDICINE FOR PEDIATRIC SOLID TUMORS
In Japan, 1 in 10,000 people develop pediatric cancer. Although there are only 2,000 to 2,500 newly diagnosed cases per year, it is the leading cause of death in children. About 500 pediatric cancer patients die each year. Currently, within the Japan Pediatric Cancer Research Group (JCCG), there are seven solid tumor subcommittees: the Neuroblastoma Committee (JNBSG); Liver Tumor Committee (JPLT); Renal Tumor Committee (JWITS); Germ Cell Tumor Committee (JGCT); Rhabdomyosarcoma Committee (JRSG); Ewing Sarcoma Committee (JESS, collaborating with orthopedic surgeons); and Brain Tumor Committee (mainly brain surgeons). The overall Solid Tumor Subcommittee cooperates with the Hematology and Oncology Subcommittee, and the foundation has been developed to promote high-quality clinical research on pediatric cancer in Japan. This report discusses the current status of stratified treatment for pediatric cancers in three disease committees (JNBSG, JPLT, JWITS) and describes the development of stratified treatment in Japan. It is expected that the JCCG and pediatric cancer base hospitals will jointly work to strengthen cooperation, including treatment consultation, with regional medical institutions that conduct clinical trials in pediatric cancer and contribute to improving treatment outcomes for pediatric cancer patients throughout Japan.
To read the PDF file you will need Adobe Reader installed on your computer.